Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .
Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
AIM To determine if obese non-insulin-dependent diabetic patients lose more weight when treated for 24 weeks ( 6 months ) with orlistat ( 120 mg t.i.d . ) , in conjunction with a hypocaloric diet plus behavioural counselling , than when treated by placebo ( t.i.d . ) plus similar instructions . The secondary objectives were to evaluate the effects on glucose profile and to determine the tolerability and safety of  orlistat . DESIGN Double-blind , parallel , r and omized , placebo-controlled , multicentre study . SUBJECTS Obese , non-insulin-dependent diabetic patients , aged 18 - 70 years old , with BMI > 27 kg/m2 , evaluated at 10 Latin-American centres , in five countries .  EFFICACY AND TOLERABILITY MEASUREMENTS : After screened , eligible patients passed by a 2-week placebo run-in period receiving a hypocaloric diet . On day 0 , patients were r and omized to orlistat or placebo for 24 weeks . At each visit , body weight , blood pressure and waist circumference were measured . At the screening visit , baseline visit ( week 0 ) , and at weeks 8 , 16 and 24 , a central laboratory was in charge of measuring fasting glucose and insulin , HbA1c , postpr and ial glucose and insulin , fasting total cholesterol , HDL-cholesterol , LDL-cholesterol , triglycerides , and postpr and ial triglycerides . Other safety laboratory assessment s were measured locally at the screening visit , baseline visit and at the end of the study . Adverse events were assessed at each visit from baseline . RESULTS After 24 weeks of treatment , the orlistat group lost an average of 4.7 % of initial body weight vs. 3.0 % in the placebo group ( p = 0.0003 ) . A greater weight loss was achieved in the orlistat compared with the placebo group ( 4.24 + /- 0.23 vs. 2.58 + /- 1.46 kg , p = 0.0003 ) . Almost twice as many patients receiving orlistat ( 30 % vs. 17 % ) lost > or = 5 % of initial body weight ( p = 0.003 ) . Orlistat treatment plus diet compared to placebo plus diet was associated with significant improvement in glycaemic control , as reflected in decreases in HbA1c ( p = 0.04 ) , fasting plasma glucose ( p = 0.036 ) and postpr and ial glucose ( p = 0.05 ) . Orlistat-treated patients had a mean decrease in glucose levels of 1.00 + /- 0.34 mmol/l [ 3.7 % ] vs. 0.01 + /- 0.30 mmol/l for placebo group , at week 24 and an absolute decrease of HbA1c of 0.61 + /- 0.15 vs. a decrease of 0.22 + /- 0.14 % in the placebo group . Orlistat therapy also result ed in significantly greater improvements than placebo in lipid profile , with reductions in total cholesterol ( p = 0.0001 ) and LDL-cholesterol ( p = 0.002 ) . Mild to moderate transient gastrointestinal events were reported , mainly with orlistat treatment , but their association with withdrawal from the study was low . CONCLUSION Orlistat is a useful and an effective therapy in obese diabetic patients , promoting clinical ly significant weight loss and improved glycaemic control and lipid profile
Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .